ATE324867T1 - Verabreichung von taxanen an angiogene blutgefässe mittels kationischer liposomen - Google Patents

Verabreichung von taxanen an angiogene blutgefässe mittels kationischer liposomen

Info

Publication number
ATE324867T1
ATE324867T1 AT00960004T AT00960004T ATE324867T1 AT E324867 T1 ATE324867 T1 AT E324867T1 AT 00960004 T AT00960004 T AT 00960004T AT 00960004 T AT00960004 T AT 00960004T AT E324867 T1 ATE324867 T1 AT E324867T1
Authority
AT
Austria
Prior art keywords
cationic liposomes
taxans
administration
blood vessels
angiogenic blood
Prior art date
Application number
AT00960004T
Other languages
English (en)
Inventor
Donald M Mcdonald
John W Mclean
O Gavin Thurston
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE324867T1 publication Critical patent/ATE324867T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00960004T 1999-09-09 2000-09-08 Verabreichung von taxanen an angiogene blutgefässe mittels kationischer liposomen ATE324867T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39297699A 1999-09-09 1999-09-09

Publications (1)

Publication Number Publication Date
ATE324867T1 true ATE324867T1 (de) 2006-06-15

Family

ID=23552795

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00960004T ATE324867T1 (de) 1999-09-09 2000-09-08 Verabreichung von taxanen an angiogene blutgefässe mittels kationischer liposomen

Country Status (21)

Country Link
US (1) US20100226970A1 (de)
EP (1) EP1210065B1 (de)
JP (2) JP4848113B2 (de)
KR (1) KR100591767B1 (de)
CN (1) CN1235567C (de)
AT (1) ATE324867T1 (de)
AU (1) AU782714B2 (de)
BR (1) BR0013866A (de)
CA (1) CA2383412C (de)
CZ (1) CZ2002850A3 (de)
DE (1) DE60027730T2 (de)
EA (1) EA005923B1 (de)
EE (1) EE200200127A (de)
ES (1) ES2258471T3 (de)
HK (1) HK1046506B (de)
HU (1) HUP0202669A3 (de)
IL (2) IL148372A0 (de)
MX (1) MXPA02002579A (de)
PL (1) PL203128B1 (de)
WO (1) WO2001017508A1 (de)
ZA (1) ZA200201555B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511426A (ja) * 2000-05-03 2004-04-15 ミュンヘン　バイオテク　アーゲー 活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
JP4778679B2 (ja) * 2001-10-03 2011-09-21 セレーター ファーマシューティカルズ インコーポレイテッド 併用薬剤を送達するための組成物
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ES2369640T3 (es) 2002-05-24 2011-12-02 Angiotech International Ag Composiciones y métodos para revestir implantes médicos.
EP1553924B1 (de) * 2002-06-26 2010-12-08 MediGene AG Neues verfahren zur stabilisierung von diagnostischen und therapeutischen verbindungen in einem kationischen trägersystem
AU2003280505B2 (en) * 2002-06-26 2009-01-15 Syncore Biotechnology Co., Ltd Method of producing a cationic liposomal preparation comprising a lipophilic compound
EP1374864A1 (de) * 2002-06-26 2004-01-02 Munich Biotech AG Amphiphile, Taxane enthaltende Zusammensetzungen
WO2004112747A2 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
CA2542217C (en) * 2003-10-15 2018-03-27 Medigene Ag Method of administering cationic liposomes comprising an active drug
JP2007517874A (ja) * 2004-01-16 2007-07-05 バーンズ−ジューイッシュ ホスピタル 標的化アテローム性動脈硬化症治療法
AU2006243337B2 (en) * 2005-05-04 2011-09-29 Syncore Biotechnology Co., Ltd Method of administering a cationic liposomal preparation comprising paclitaxel
CA2922029C (en) 2006-03-22 2017-11-28 Medigene Ag A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent
EP2259798B1 (de) 2008-03-05 2013-12-11 Baxter International Inc. Zusammensetzungen und verfahren zur wirkstofffreisetzung
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US9706903B2 (en) 2009-06-18 2017-07-18 Endochoice, Inc. Multiple viewing elements endoscope system with modular imaging units
DE102009032658A1 (de) * 2009-07-09 2011-01-13 Forschungszentrum Jülich GmbH Mischung amphipathischer Moleküle und Verfahren zur Zellmembranmodifikation durch Fusion
KR101007925B1 (ko) * 2009-10-07 2011-01-14 건일제약 주식회사 경구용 지질 나노입자 및 그의 제조방법
ES2923929T3 (es) * 2016-10-28 2022-10-03 Servier Lab Formulación liposomal para uso en el tratamiento del cáncer
KR102250123B1 (ko) 2019-11-25 2021-05-10 주식회사 현대케피코 무단 변속기의 제한 목표 기어비 학습 방법
KR102261482B1 (ko) 2019-12-10 2021-06-07 주식회사 현대케피코 무단 변속기의 킥다운 시프트 직후 구동 풀리 제어 압력 보정 방법 및 장치

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0470569B1 (de) * 1990-08-08 1995-11-22 Takeda Chemical Industries, Ltd. Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
PT706373E (pt) * 1992-03-23 2000-11-30 Univ Georgetown Taxol encapsulado num liposoma e um metodo
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
ATE249448T1 (de) * 1993-06-11 2003-09-15 Upjohn Co Delta 6,7-taxol derivate antineoplastische verbindungen und diese enthaltende pharmazeutische zusammenstellungen
EP0711158B2 (de) * 1993-07-29 2008-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren zur behandlung atherosklerose oder restenose mit hilfe eines mikrotubulusstabilisators
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5641755A (en) * 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
DE19605274A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
KR100561788B1 (ko) * 1996-03-12 2006-09-20 피지-티엑스엘 컴파니,엘.피. 수용성파클리탁셀전구약물을포함하는조성물및이러한조성물을포함하는이식가능한의료장치
US5935937A (en) * 1996-06-19 1999-08-10 Fox Chase Cancer Center Compositions and methods for inducing apoptosis
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
WO2000047235A2 (en) * 1999-02-10 2000-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of stimulating angiogenesis
ES2358416T3 (es) * 2001-10-30 2011-05-10 Novartis Ag Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella.

Also Published As

Publication number Publication date
EP1210065A1 (de) 2002-06-05
CA2383412A1 (en) 2001-03-15
US20100226970A1 (en) 2010-09-09
JP4848113B2 (ja) 2011-12-28
EE200200127A (et) 2003-04-15
EP1210065A4 (de) 2004-04-28
JP2003514768A (ja) 2003-04-22
PL203128B1 (pl) 2009-08-31
MXPA02002579A (es) 2003-10-14
CA2383412C (en) 2010-02-02
KR100591767B1 (ko) 2006-06-23
DE60027730D1 (de) 2006-06-08
CN1235567C (zh) 2006-01-11
CN1378443A (zh) 2002-11-06
ES2258471T3 (es) 2006-09-01
ZA200201555B (en) 2003-04-30
DE60027730T2 (de) 2007-03-29
IL148372A0 (en) 2002-09-12
HUP0202669A3 (en) 2004-06-28
BR0013866A (pt) 2002-05-14
IL148372A (en) 2007-09-20
KR20030038530A (ko) 2003-05-16
CZ2002850A3 (cs) 2003-04-16
WO2001017508A1 (en) 2001-03-15
AU782714B2 (en) 2005-08-25
AU7122900A (en) 2001-04-10
EA200200229A1 (ru) 2003-06-26
HK1046506A1 (en) 2003-01-17
WO2001017508A9 (en) 2002-10-03
EP1210065B1 (de) 2006-05-03
HUP0202669A2 (hu) 2004-05-28
EA005923B1 (ru) 2005-08-25
JP2010280667A (ja) 2010-12-16
PL354721A1 (en) 2004-02-09
HK1046506B (zh) 2006-08-25

Similar Documents

Publication Publication Date Title
ATE324867T1 (de) Verabreichung von taxanen an angiogene blutgefässe mittels kationischer liposomen
NO994413D0 (no) Kationiske lipidblandinger mÕlsökende angiogene endotelceller
Sugahara et al. The cytotoxic effect of Eucheuma serra agglutinin (ESA) on cancer cells and its application to molecular probe for drug delivery system using lipid vesicles
DE69529174D1 (de) Zellzyklus regulierte repressor und dna-element
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
Valacchi et al. Ozone mediators effect on “in vitro” scratch wound closure
ATE331802T1 (de) Sequenz-spezifische dna-rekombination in eukaryotischen zellen
ATE109357T1 (de) Transdermales estradiol als therapeutisches sytem.
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
DE69130569D1 (de) Mit psoralen konjugierte methylphosphonat-oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie
Choudhury et al. Synthesis and DNA cleavage activity of a novel bleomycin A5 glycoconjugate
Sukhanova et al. Human DNA‐topoisomerase I activity is affected by bis‐netropsin's binding to DNA minor groove
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
DE60138762D1 (de) Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren
Zychlinsky Necrosis and apoptosis: Cell death in the immune system.
AR026246A1 (es) Proteinas hcv reversibles redox con conformacion de tipo nativo
Kotnik et al. PULA, CROATIA June 11, 2001
TH72418A (th) แทรป vegf และการใช้ทางการบำบัดของมัน
TH33765A (th) ตัวกระตุ้นฤทธิ์เอนไซม์นิวคลีเอสของเซลล์มะเร็ง

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1210065

Country of ref document: EP